sar425899 sanofi dual agonist glp-1 glucagon Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity Role of a Dual Glucose-Dependent
Description
While GLP-1...
Thirteen trials involving 5,807 participants were identified
In the subgroup analyses, human GLP-1 RAs, but not nonhuman GLP-1 RAs, reduced the risk of MACE in patients with HF (p interaction = 0.11)
THIRD-PARTY TESTED, AND DOCTOR RECOMMENDED: Manufactured in the USA in FDA-reviewed, NSF and GMP certified facilities to ensure the highest standards of safety and effectiveness
The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023
They also offer the
